Trials / Terminated
TerminatedNCT02698384
Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 4 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to evaluate the biochemical and clinical effectiveness on symptoms and tumor size of a monotherapy with Lanreotide 120mg in acromegalic subjects, to describe criteria for starting alternative strategies, and to describe the modalities and the global effectiveness of alternative strategies.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-06-01
- First posted
- 2016-03-03
- Last updated
- 2018-12-21
Locations
10 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02698384. Inclusion in this directory is not an endorsement.